Utilizing G2/M retention effect to enhance tumor accumulation of active targeting nanoparticles

Guanlian Hu1, Xingli Cun1, Shaobo Ruan1

  • 1Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 610041, China.

Scientific Reports
|June 9, 2016
PubMed

Insights

This study shows that synchronizing tumor cells in the G2/M phase with docetaxel (DTX) enhances the tumor targeting of folic acid (FA) modified nanoparticles (NPs). This simple strategy improves nanoparticle delivery for potential cancer therapy.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Active targeting of nanoparticles (NPs) to tumors via ligand modification faces challenges in clinical translation due to complex preparation, poor stability, and toxicity.
  • Nanoparticle internalization is linked to the cell cycle, and receptor expression varies with cancer type and cell cycle stage.

Purpose of the Study:

  • To investigate the relationship between cell cycle and ligand-modified NP internalization.
  • To develop a novel strategy for enhancing active tumor targeting of NPs by manipulating the cell cycle.

Main Methods:

  • Utilized chemotherapeutics to synchronize tumor cells in the G2/M phase.
  • Studied the cellular uptake of folic acid (FA) modified NPs (FANPs) in G2/M synchronized cells.
  • Evaluated the in vitro and in vivo targeting efficacy of DTX-pretreated FANPs.

Main Results:

  • Docetaxel (DTX) effectively synchronized tumor cells in the G2/M phase.
  • Pretreatment with DTX significantly improved the in vitro and in vivo tumor cell targeting of FA-decorated NPs (FANPs).

Conclusions:

  • Cell cycle synchronization is a viable strategy to enhance the active targeting of ligand-modified NPs.
  • This DTX-induced G2/M phase arrest strategy offers a simple and effective method for improving FANP tumor accumulation, with broad clinical application prospects.

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
74
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
83